NuCana (NCNA) News
NASDAQ: NCNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.7495+0.0315 (+4.39%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NCNA news summary
We found 4 recent headlines mentioning NuCana (NCNA): 3 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, NCNA is up 4.39% at $0.7495. The most recent story, "NuCana's NUC-7738 Enhances Carfilzomib Activity In Multiple Myeloma Treatment", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest NuCana headlines
- NuCana's NUC-7738 Enhances Carfilzomib Activity In Multiple Myeloma Treatment(RTTNews) - Friday, NuCana plc (NCNA) announced new preclinical data on NUC-7738, showing that it enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor for the treatment…NasdaqNCNA, UHAL.B
- NuCana plc Announces Preclinical Data Showing NUC-7738 Enhances Carfilzomib ActivityNuCana plc announced new preclinical data showing that NUC-7738 enhanced the anti-cancer activity of carfilzomib, an approved proteasome inhibitor used to treat patients with multiple myeloma. The…NasdaqNCNA, SUN
- NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR SymposiumNUC-7738 Increased Proteasome Inhibition When Combined with CarfilzomibGlobeNewswire
- NuCana Reports Third Quarter 2026 Financial Results and Provides Business UpdateDevelopment Programme for NUC-7738 Advances with Three Presentations Planned at ESMO Immuno-Oncology & Advanced Therapies Congress in December 2026GlobeNewswire